| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C22H16F4N4OS |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
ULK-101 is a potent and selective ULK1 inhibitor, with IC50 values of 1.6 nM for ULK1 and 30 nM for ULK2. It suppresses autophagy and sensitizes cancer cells to nutrient stress[1]. It is supplied as a light yellow to yellow solid (C22H16F4N4OS, MW 460.45) at 99.91% purity.
Physical & Chemical Properties
| CAS Number | 2443816-45-1 |
|---|---|
| Molecular Formula | C22H16F4N4OS |
| Molecular Weight | 460.45 g/mol |
| Purity | 99.91% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | FC1=CC=C(C(C=N2)=CN3C2=C(C4=CSC(C(N[C@@H](C5CC5)C(F)(F)F)=O)=C4)C=N3)C=C1 |
| Target | ULK1, ULK2 |
| Signaling Pathway | Autophagy |
| Solubility | In Vitro: DMSO: 83.33 mg/mL (180.98 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[1]
|
ULK1 1.6 nM (IC50) |
ULK2 30 nM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 83.33 mg/mL (180.98 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (4.52 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Data provided by the manufacturer.
In Vitro
In U2OS cells, ULK-101 (0-5 μM) reduces BafA1-induced LC3B-II accumulation in a concentration-dependent manner[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. Nat Commun 2026 Feb 12;17(1):1214. PMID: 41680175
Semaglutide administration protects cardiomyocytes in db/db mice via energetic improvement and mitochondrial quality control. Acta Pharmacol Sin 2025 May;46(5):1250-1261. PMID: 39856432
A nature-inspired nanoplatform for multi-protein targeted degradation via the autophagy-lysosome pathway. Cell Chem Biol 2026 Apr 16;33(4):523-537.e7. PMID: 41932333
Oleanolic acid blocks the purine salvage pathway for cancer therapy by inactivating SOD1 and stimulating lysosomal proteolysis. Mol Ther Oncolytics 2021 Aug 28:23:107-123. PMID: 34703880
Targeting the DSTYK-ULK1 axis rewires TNFR1 signaling to overcome treatment resistance in lung cancer. Cell Rep 2026 Mar 12;45(3):117087. PMID: 41824459
The Lnc-Gm20716/miR-20b-5p/ULK1 axis regulates HDM-induced endoplasmic reticulum stress and Golgi fragmentation in mouse bronchial epithelial cells. Int Immunopharmacol 2025 Aug 28:161:115095. PMID: 40532330
Design, synthesis and biological evaluation of benzimidazole carbamide derivatives - potential autophagy inducers. Bioorg Med Chem 2026 Jul:138:118646. PMID: 41934864
Università Vita-Salute San Raffaele. 2022 Apr 08. 34.
The University of Chicago. Pritzker School of Medicine. 2021 Oct.
